Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Asset Writedowns and Impairment (2023 - 2025)

Allogene Therapeutics' Asset Writedowns and Impairment history spans 2 years, with the latest figure at $2.4 million for Q2 2025.

  • For Q2 2025, Asset Writedowns and Impairment fell 52.36% year-over-year to $2.4 million; the TTM value through Jun 2025 reached $8.6 million, changed N/A, while the annual FY2024 figure was $6.2 million, 53.03% down from the prior year.
  • Asset Writedowns and Impairment for Q2 2025 was $2.4 million at Allogene Therapeutics, up from -$9.5 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $10.7 million in Q3 2024 and bottomed at -$9.5 million in Q4 2024.